Sm-TSP-2/Alhydrogel

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Schistosomiasis

Phase 1

A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults

CompletedNCT02337855

National Institute of Allergy and Infectious Diseases (NIAID)Schistosomiasis

Start: 2015-02-04End: 2017-01-27Updated: 2017-06-26

A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults

CompletedNCT03110757

National Institute of Allergy and Infectious Diseases (NIAID)Schistosomiasis

Start: 2018-05-20End: 2019-11-14Updated: 2021-02-02

Related Papers

A randomized, controlled Phase 1b trial of the Sm-TSP-2 Vaccine for intestinal schistosomiasis in healthy Brazilian adults living in an endemic area

PLoS neglected tropical diseases2023-03-3026 citations